Fuji Pharma Co., Ltd. (TYO:4554)

Japan flag Japan · Delayed Price · Currency is JPY
2,252.00
-94.00 (-4.01%)
Mar 9, 2026, 3:30 PM JST
66.20%
Market Cap 55.11B
Revenue (ttm) 54.57B
Net Income (ttm) 2.33B
Shares Out 24.47M
EPS (ttm) 95.47
PE Ratio 23.59
Forward PE 15.35
Dividend 47.00 (2.00%)
Ex-Dividend Date Mar 30, 2026
Volume 237,100
Average Volume 300,970
Open 2,181.00
Previous Close 2,346.00
Day's Range 2,168.00 - 2,263.00
52-Week Range 1,180.00 - 2,446.00
Beta 0.37
RSI 52.62
Earnings Date May 7, 2026

About Fuji Pharma

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmaceuticals and health services, as well as contract manufacturing services. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, ... [Read more]

Sector Healthcare
Founded 1965
Employees 1,760
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4554
Full Company Profile

Financial Performance

In fiscal year 2025, Fuji Pharma's revenue was 51.68 billion, an increase of 12.01% compared to the previous year's 46.14 billion. Earnings were 3.00 billion, a decrease of -51.19%.

Financial Statements

News

Alvotech Receives Marketing Approval In Japan For Three New Biosimilars

(RTTNews) - Luxembourg-based biotechnology company Alvotech SA (ALVO) announced Friday that its commercialization partner in Japan, Fuji Pharma Co., Ltd. has received marketing approval for three new ...

6 months ago - Nasdaq

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO , ALVO SDB, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients w...

9 months ago - Benzinga

Olic anticipates buoyant demand for contraceptives

The contraceptive market is expected to grow in Southeast Asia, driven by informed individuals' increasing awareness of health issues and a trend of having no children, says Olic (Thailand) Ltd, a sub...

1 year ago - Bangkok Post